Company intelligence / Profile preview

Stella Diagnostics

Ownership: Public · SLDX
Development stage: Preclinical

Overview

Stella Diagnostics is developing STLA101, a targeted mass spectrometry proteomics-based diagnostic tool designed to provide robust molecular data from diseased esophageal tissue. The goal is to inform physicians about disease stability or progression toward cancer earlier than current standards allow. As of now, the lead product remains in the discovery phase and has not yet reached clinical trials or commercialization.

Therapeutic areas: GastroenterologyOncology
Modalities: Diagnostic assayProteomic assay
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

BE-smart

Pre-clinical

Indications: Barrett's esophagus

Financials

Market cap: $786.3K
Total revenue: $501.1K
Enterprise value: $14.9M

Beyond the preview

Go deeper on Stella Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stella Diagnostics.

Explore the full profile